
Please try another search
ImmunoPrecise Antibodies Ltd. operates as a AI-driven biotherapeutic research and technology company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies. It is also involved in the development and licensing of antibody discovery platforms and related IP assets. The company was founded in 1983 and is based in Seri Kembangan, Malaysia.
Name | Age | Since | Title |
---|---|---|---|
Jennifer Lynne Bath | - | 2018 | CEO, President & Non-Independent Director |
Dirk Witters | - | 2023 | Independent Chairman of the Board |
Jonathan I. Lieber | 55 | 2025 | Independent Director |
Kamil Isaev | - | 2025 | Independent Director |
Jeff Fried | - | 2025 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review